| (Values in U.S. Thousands) | Jun, 2025 | Dec, 2024 | Jun, 2024 | Dec, 2023 | Jun, 2023 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Kazia Therapeutics Ltd ADR (KZIA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kazia Therapeutics Limited is an oncology-focused biotechnology company. It develops anti-cancer drugs as well as provides pharmaceutical research and development technology solutions. The company's lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, is based in Sydney, Australia.
Fiscal Year End Date: 06/30